Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Apr;21(4):404-17.
doi: 10.1634/theoncologist.2015-0351. Epub 2016 Feb 10.

Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications

Affiliations

Obesity and Breast Cancer: Molecular Interconnections and Potential Clinical Applications

Valeria Simone et al. Oncologist. 2016 Apr.

Abstract

Obesity is an important risk factor for breast cancer (BC) in postmenopausal women; interlinked molecular mechanisms might be involved in the pathogenesis. Increased levels of estrogens due to aromatization of the adipose tissue, inflammatory cytokines such as tumor necrosis factor-α, interleukin-6, and prostaglandin E2, insulin resistance and hyperactivation of insulin-like growth factors pathways, adipokines, and oxidative stress are all abnormally regulated in obese women and contribute to cancerogenesis. These molecular factors interfere with intracellular signaling in the mitogen-activated protein kinase and phosphatydilinositol-3-phosphate/mammalian target of rapamycin (mTOR) pathways, which regulate the progression of the cell cycle, apoptosis, and protein synthesis. In this context, structural defects of typical genes related to both BC and obesity, such as leptin, leptin receptor, serum paraoxonase/arylesterase 1, the fat mass and obesity-associated gene and melanocortin receptor 4, have been associated with a high or low risk of BC development. The early detection of these gene alterations might be useful as risk predictors in obese women, and targeting these pathways involved in the BC pathogenesis in obese women is a potential therapeutic tool. In particular, mTOR pathway deregulation concurs in both obesity and BC, and inhibition of this might disrupt the molecular interlinks in a similar manner to that of metformin, which exerts definite anticancer activity and is currently used as an antidiabetic drug with a weight-reducing property. The identification of both genetic and pharmacological implications on the prevention and management of BC is the ultimate aim of these studies.

Implications for practice: Obese women are at risk of breast cancer, but clinicians lack concrete tools for the prevention or early diagnosis of this risk. The present study, starting from the biology and the molecular defects characterizing both obesity and breast cancer, analyzed the potential molecules and genetic defects whose early identification could delineate a risk profile. Three steps are proposed that are potentially achievable in the clinical assessment of obese women, namely the evaluation of altered levels of serum molecules, the identification of genetic polymorphisms, and the study of the transcriptomic profile of premalignant lesions. Finally, the therapeutic implications of this molecular assessment were evaluated.

摘要

肥胖是绝经后女性乳腺癌的重要危险因素, 发病机制可能涉及共通的分子机制。肥胖女性的脂肪组织芳香化导致的雌激素水平升高、炎性细胞因子 (如肿瘤坏死因子α、白介素6、前列腺素E2) 、胰岛素抵抗和胰岛素样生长因子旁路超活化、脂肪细胞因子及氧化应激均处于调节异常状态并可促进癌症形成。这些分子因素干扰细胞内信号转导中的丝裂原活化蛋白激酶和磷脂酰肌醇-3-磷酸/哺乳动物雷帕霉素靶蛋白 (mTOR) 通路, 而这些通路可调控细胞周期进展、凋亡和蛋白质合成。因此, 与乳腺癌和脂肪均相关的典型基因 (如瘦素、瘦素受体、血清对氧磷酶/芳香酯酶1、脂肪量与肥胖相关基因和黑素皮质素受体4) 的结构缺陷与乳腺癌发生风险升高或降低有关。早期发现这些基因改变可能有助于预测肥胖女性的风险, 针对肥胖女性中这些乳腺癌发病机制涉及的通路进行治疗也可能具有潜力。特别是肥胖和乳腺癌都会发生mTOR通路调节紊乱, 对其加以抑制也许能破坏二者的分子内在联系, 类似当前作为具有减轻体重作用的降糖药使用的二甲双胍却能发挥确切的抗癌活性那样。这些研究的终极目标是确定乳腺癌管理和预防措施的遗传和药理学意义。The Oncologist 2016;21:404–417

对临床实践的提示: 肥胖女性有发生乳腺癌的风险, 但临床医生缺乏具体的工具以预防或早期诊断这种风险。本研究中, 开篇讲述了肥胖和乳腺癌的生物学和分子缺陷特征, 分析了通过早期鉴别分子和基因缺陷可能绘制出风险谱。我们对肥胖女性的临床评估提出了三个可能达到的步骤, 即对血清分子水平的改变进行评价、鉴别基因多态性, 以及对癌前病变的转录组学特征进行研究。最后, 我们评价了这一分子评估的治疗意义。

Keywords: Adipokines; Breast cancer; Insulin resistance; Obesity; Polymorphisms; Risk factors.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

Figures

Figure 1.
Figure 1.
Molecular breast cancer (BC)-related pathways activated in obesity. In obese patients, estrogens, insulin, IGFs, and adipokines activate pathways shown to be deregulated in BC. The estrogen receptor complex migrates to the nucleus and binds the EREs in promoters of target genes that regulate cell survival. Obesity causes increased levels of insulin, IGF-I, and IGF-II that bind the IR, IGF-IR, and a hybrid form (IR-IGF-IR), and thus activate both the RAS/MEK/MAPK and PI3K/Akt/mTOR pathways converging on S6K1. Phosphorylation of S6rp by S6K1 promotes both protein synthesis and cell proliferation. Leptin activates JAK/STAT signaling by its receptor (OB-R). Adiponectin triggers AMPK through its receptor AdipoR. AMPK phosphorylation decreases the nuclear translocation of CRTC2 that binds CREB, thus increasing the aromatase activity. These pathways, converging on NF-κB, lead to the expression of CyclD1 and c-Myc, which promotes cell survival and proliferation, as well as the secretion of VEGF and tumor angiogenesis. ROS contribute to the tumor progression, favoring the genomic instability. Abbreviations: AdipoR, adiponectin receptor; AMPK, AMP-activated protein kinase; CREB, cAMP response element-binding protein; CRTC2, CREB-regulated transcription coactivator 2; CyclD1, cyclin D1; EREs, estrogen response elements; IGF, insulin-like growth factor; IGF-IR, IGF-I receptor; IR, insulin receptor; JAK2/STAT3, janus kinase 2/signal transducer and activator of transcription 3; NF-κB, nuclear factor κB; PI3K, phosphatydilinositol-3-phosphate; ROS, reactive oxygen species; S6K1, S6 kinase-1; S6rp, S6 ribosomal protein; VEGF, vascular endothelial growth factor.
Figure 2.
Figure 2.
Breast tissue microenvironment: stromal-epithelial interactions. Adipose tissue is a permissive environment for breast cancer (BC). Malignant epithelial cells establish close interactions with adipose fibroblasts that differentiate into mature adipocytes. BC cells produce IL-11, TNF-α, and PGE2. IL-11 and TNF-α act as antiadipogenic cytokines and PGE2 reinforces the aromatase expression priming PKA and PKC. PKA activates transcription factor C/EBPβ that binds the key cis-regulatory element C/EBPβS in proximity of the PI.3, and PKC activates the LRH-1 transcription factor whose binding site is located more proximal to PII. Abbreviations: IL-11, interleukin-11; LRH-1, liver receptor homolog-1; PGE2, prostaglandin E2; PI.3, promoter I.3 region; PII, promoter II; PKA, protein kinase A; PKC, protein kinase C; TNF-α, tumor necrosis factor-α.
Figure 3.
Figure 3.
Drugs interfering with breast cancer (BC)- and obesity-related pathways. Drugs commonly used in BC, obesity, and diabetes interfere with intracellular signaling hyperactivation in BC. Aromatase inhibitors inhibit enzyme aromatase in the conversion of androgens, such as testosterone and androstenedione, to estrogens, such as estradiol and estrone. SERMs, such as tamoxifen, bind to estrogen receptors and induce conformational changes that inhibit the expression of estrogen-related genes. In BC cells, high levels of proinflammatory cytokines such as TNF-α, typical in obese patients, activate IKKB that phosphorylates IkB, thus activating NF-κB, composed of its subunits p50 and p65. Furthermore, phosphorylation of TSC1 by IKKB activated by mTOR kinase is involved in cell growth and angiogenesis. Drugs targeting IKKB, such as aspirin, and mTOR inhibitors, such as everolimus and rapamycin, are potentially effective as anti-BC drugs in obese women. Metformin, an antidiabetes drug that can effectively reduce body weight, activates AMPK, which phosphorylates TSC2, having an inhibitory effect on mTOR. Activation of the mTOR pathway leads to the production of VEGF, mediated by transcription factor HIF1α, which could be targeted by bevacizumab. Abbreviations: AMPK, AMP-activated protein kinase; EREs, estrogen response elements; HIF1α, hypoxia inducible factor-1α, IKKB, IkB kinase β; NF-κB, nuclear factor κB; SERMs, selective estrogen receptor modulators; TNF-α, tumor necrosis factor-α; VEGF, vascular endothelial growth factor.
Figure 4.
Figure 4.
Arbitrary BC risk grading in obese women. Considering the molecular interlinks between obesity and BC, clinical assessment of the BC risk in obese women should include three steps. The first step is to measure the serum levels of inflammatory cytokines, adipokines, insulin, IGFI, and estradiol. The second step should include the assessment of both obesity and BC-related genetic derangements such as SNPs of LEP, LEPR, PON1, FTO, MC4R, ADIPOQ, TNFα, IGFI, and PR. In the case of premalignant or suspicious lesions, the third step would include the analysis of the transcriptomic profile related to biological processes such as EMT, protein synthesis, Notch signaling, the lipid and cholesterol metabolism, inflammation, proliferation, adipokines, cell adhesion, estrogen receptor signaling, and others. Abbreviations: EMT, epithelial-to-mesenchymal transition; IGFI, insulin-like growth factor I; SNPs, single nucleotide polymorphisms.

Similar articles

Cited by

References

    1. World Cancer Research Fund/American Institute for Cancer Research . Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR; 2007.
    1. Key TJ, Appleby PN, Reeves GK, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95:1218–1226. - PubMed
    1. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: Cohort study. BMJ. 2007;335:1134. - PMC - PubMed
    1. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–578. - PubMed
    1. Vainio H, Bianchini F.Weight Control and Physical Activity, Vol. 6. IARC Handbook of Cancer Prevention Lyon, France: IARC Press; 2002:1–315.

Publication types

MeSH terms